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AbsTrACT
This study explored experiences, perceptions and views 
among World Health Organization (WHO) staff about 
the changes, progress and challenges brought by the 
guideline development reforms initiated in 2007. Thirty-
five semistructured interviews were conducted with 
senior WHO staff. Sixteen of the interviewees had in-depth 
experience with WHO’s formal guideline development 
process. Thematic analysis was conducted to identify key 
themes in the qualitative data, and these were interpreted 
in the context of the existing literature on WHO’s guideline 
development processes. First, the reforms were seen to have 
transformed and improved the quality of WHO’s guidelines. 
Second, independent evaluation and feedback by the 
Guidelines Review Committee (GRC) was described to have 
strengthened the legitimacy of WHO’s recommendations. 
Third, WHO guideline development processes are not yet 
designed to systematically make use of all types of research 
evidence needed to inform decisions about health systems 
and public health interventions. For example, several 
interviewees expressed dissatisfaction with the insufficient 
attention paid to qualitative evidence and evidence 
from programme experience, and how the Grading of 
Recommendations Assessment, Development and Evaluation 
(GRADE) process evaluates the quality of evidence from non-
randomised study designs, while others believed that GRADE 
was just not properly understood or applied. Fourth, some 
staff advocated for a more centralised quality assurance 
process covering all outputs from WHO’s departments 
and scientific advisory committees, especially to eliminate 
strategic efforts aimed at bypassing the GRC’s requirements. 
Overall, the ‘culture change’ senior WHO staff called for over 
10 years ago appears to have gradually spread throughout 
the organisation. However, at least two major challenges 
remain: (1) ensuring that all issued advice benefits from 
independent evaluation, monitoring and feedback for quality 
and (2) designing guideline development processes to better 
acquire, assess, adapt and apply the full range of evidence 
that can inform recommendations on health systems and 
public health interventions.
InTroduCTIon
In 2007, the World Health Organization 
(WHO) embarked on far-reaching reforms 
of its guideline development process. The 
major driving factor was a study published 
by Oxman, Lavis and Fretheim in The Lancet 
that identified at least four flaws in the agen-
cy’s guideline development processes.1 First, 
systematic and transparent methods for 
retrieving, appraising, synthesising and inter-
preting evidence were rarely used. Second, 
WHO’s guideline development processes 
rarely involved methodologists or repre-
sentatives of populations affected by the 
Key questions
What is already known?
 ► Previous studies of WHO’s guidelines have primarily 
focused on the outputs of the guideline develop-
ment processes, while the experience of WHO staff 
with these processes have received relatively less 
attention. 
What are the new findings?
 ►  WHO’s Guidelines Review Committee—which over-
sees formal guideline development at WHO—is a 
key institutional mechanism for securing indepen-
dent evaluation, monitoring and feedback.
 ►  WHO’s guideline development processes (especially 
about complex interventions) are not yet designed 
to systematically make use of all types of relevant 
research evidence. 
 ►  WHO’s technical departments and scientific adviso-
ry committees still issue guidance without subject-
ing these to WHO’s formal guideline development 
processes. 
What do the new findings imply?
 ► WHO should promote systematic sharing of experi-
ences and learning among its departments, system-
atically apply the full range of research evidence and 
consider centralised quality assurance processes for 
all products with normative content.
 ►  Other technical health agencies and institutions 
could learn from WHO’s mechanisms for ensuring 
independent evaluation, monitoring and feedback 
for process and quality in guideline development. 
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recommendations. Third, limited efforts were made to 
adapt global recommendations to local needs, condi-
tions, resources, costs and values. Fourth, dissemination 
and implementation strategies, and rigorous evaluations 
of these, were largely absent.
WHO quickly acknowledged the criticism and prom-
ised an immediate response.2 Several key changes to 
strengthen WHO’s guideline development process 
followed (figure 1). A new guideline development 
process was set up to involve different groups—internal 
and external to the agency—with specified roles and 
responsibilities (box 1). To ensure a transparent and 
evidence-informed decision-making process for every 
formal guideline issued by the agency, WHO established 
a Guidelines Review Committee (GRC). The GRC was set 
up in 2007 as a scientific oversight committee tasked with 
independently reviewing all guideline proposals from 
WHO’s departments prior to initiating the guideline 
development process and to approve the final guidelines 
once completed. An essential part of ensuring transpar-
ency and rigour was prioritising the use of systematic 
reviews to inform guideline development and the use 
of the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) tool.3 The GRADE 
approach represents a systematic and transparent frame-
work for appraising the quality of the evidence informing 
recommendations and making judgements about the 
strength of the recommendations. Two editions of a Hand-
book for Guideline Development have also been produced.4 5
It is now over 10 years since WHO implemented its 
guideline development reforms. Previous studies of 
WHO’s guidelines have focused on the outputs of guide-
line development processes, including assessing the 
quality of the evidence underlying recommendations,6–10 
identifying explanations for issuing discordant recom-
mendations11 12 and identifying challenges with imple-
menting the GRADE approach.9–11 13–15 Only one study, 
published 5 years ago, focused on examining the views 
and perceptions of WHO staff about the reforms.9 That 
study identified mixed views about whether WHO needed 
a single quality assurance mechanism, and uncertainties 
and lack of capacity among staff in applying the GRADE 
approach, concluding that quality assurance standards 
set by the GRC were yet to be fully embedded within the 
agency.9 This study builds on previous studies and was 
conducted as part of a larger research project examining 
the design and effectiveness of WHO’s scientific advisory 
committees. Specifically, the research objectives of this 
study were to investigate WHO staff’s experience with, 
perceptions of and views about the changes brought by 
WHO’s guideline development reforms, the progress 
and impact of these reforms to date, and key challenges 
that need to be addressed.
MeTHods
study design
This study used a qualitative study design involving primary 
data collection consisting of semistructured interviews 
with senior WHO staff. The analytical approach involved 
identification and interpretation of themes in the quali-
tative data describing key experiences, perceptions and 
views about WHO’s guideline development reforms. This 
study did not operate with explicitly defined theoretical 
frameworks to guide the scope of the study, the specifi-
cation of the research questions, or support interpreta-
tion; instead, the major themes identified in the qualita-
tive data were interpreted in the context of the existing 
literature on WHO’s guideline development process and 
guideline development more generally.
To identify major themes in the qualitative data, we 
followed the five-cycle process described by Yin (described 
in greater detail in the Data analysis section).16 Yin does 
not explicitly describe this process as ‘thematic anal-
ysis’; yet this analytical process involves identification of 
themes capturing ‘something important about the data in 
relation to the research question’,17 and representing an 
‘idea or concept that captures and summarises the core 
point of a coherent and meaningful pattern in the data’.18 
Accordingly, the methodological approach described 
Figure 1 Key events and changes during the evolution of WHO’s guideline development process.
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below resembles Braun & Clark’s six phases of thematic 
analysis: (1) familiarisation with the data, (2) coding, (3) 
searching for themes, (4) reviewing themes, (5) defining 
and naming themes and (6) writing up.17 Moreover, the 
way our findings have been identified, interpreted and 
presented under ‘Results’ is broadly consistent with the 
box 1 Key features of WHo’s guideline development process*
What is a WHo recommendation?
WHO describes a recommendation to tell ‘the intended end-user of the guideline what he or she can or should do in specific situations to achieve 
the best health outcomes possible, individually or collectively’ and to offer ‘a choice among different interventions or measures having an anticipated 
positive impact on health and implications for the use of resources’.
Furthermore, WHO’s handbook emphasises that ‘guidelines must have a clearly defined target audience (end-user) which is identified early in the 
guideline development process’ and that ‘the recommendations need to be tailored to that audience’. The target audience of guidelines are typically 
either policy-makers, managers in the health sector or health professionals. WHO recommendations help end-users ‘make informed decisions on 
whether to undertake specific interventions, clinical tests or public health measures, and on where and when to do so, and to help the user to select 
and prioritise across a range of potential interventions’.
Who initiates a WHo guideline development process?
Technical departments in WHO initiate and coordinate the guideline development process. WHO generally develops guidelines in response to needs 
expressed by its Member States, WHO country offices, external experts or other stakeholders for guidance on a clinical or public health problem or 
policy area.
What type of committees are established and how are these constructed?
Four different groups are established when developing WHO guidelines: (1) a steering group, (2) a guideline development group (GDG), (3) an external 
review group and (4) a systematic review team.
1. The steering group is led by the responsible technical officer from the technical department overseeing the guideline development process. Among 
its responsibilities include drafting the scope of the guideline, identifying the systematic review team and guideline methodologist, and submitting 
the planning proposal to the Guidelines Review Committee (GRC). The steering group is usually exclusively composed of members from all WHO 
departments and regional offices whose work deal directly with the topic of the guideline. In cases where the guideline is developed jointly with 
another UN agency, individuals from that agency will also be members of the steering group.
2. The GDG is composed of external experts, and its central task is to develop the evidence-informed recommendations. Its composition should re-
flect the technical skills, geographic representation and diverse perspectives (including end-users and representatives of people and communities 
affected by the recommendations) needed to produce the guideline. Its membership does not include employees of WHO or other UN agencies. The 
GDG is established early in the process once the steering group has defined the general scope and target audience of the guideline and drafted key 
questions. The GDG is responsible for finalising the scope and key questions of the guideline. Members do not receive any financial compensation 
other than for direct expenses associated with their work on the guideline.
3. The external review group is composed of technical experts, end-users, programme managers, advocacy groups and individuals from communities 
affected by the recommendations. Similar to the GDG, the external review group should be balanced in terms of geography and gender and should 
involve diverse perspectives. If important perspectives and stakeholders are missing from the GDG, these should be represented in the external 
review group. Members of the external review group can be asked to participate in different stages of the guideline development process, such 
as reviewing the guideline’s scope and key questions, reviewing the final guideline for errors or missing data and commenting on implications for 
implementation.
4. The systematic review team are usually external groups commissioned by WHO to undertake systematic reviews of the evidence base underpinning 
the key questions identified by the steering committee and the GDG. Ideally, the systematic review team is identified early and involved in formulating 
the key questions and establishing a reasonable scope for the guidelines.
What role does the methodologist play during the guideline development process?
WHO Handbook for Guideline Development recommends that at least one methodologist—defined as an expert in guideline development processes 
and methods—should be involved in the development of WHO guidelines. The methodologist should be an expert in systematic reviews, GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) and translating evidence into recommendations. The process should recruit 
them early to enable their participation in planning, scoping and developing the key questions. During the GDG meetings, the methodologist supports 
the GDG to ensure that recommendations are informed by the evidence in a transparent and explicit manner.
What is the composition and role of the GrC?
The GRC was established by WHO’s Director General in 2007 to ensure that WHO guidelines are of high quality, are developed using a transparent 
and explicit process, and to the extent possible, are evidence-based. The GRC is composed of approximately 30 individuals. Five of these are external, 
while the remaining are WHO staff from headquarters and regional offices (Susan L Norris, personal communication, 2018). WHO’s Member States do 
not have representatives in the GRC, and the GRC members serve in their individual capacity (Susan L Norris, personal communication, 2018). The 
GRC meets monthly to review submitted documents. All WHO publications containing recommendations must be approved by the GRC according to 
WHO policies and procedures. The GRC reviews every WHO guideline at the initial planning stage and again after the recommendations have been 
developed and the guideline document has been finalised and edited. GRC approval is part of WHO’s internal clearance processes for the publication 
of guidelines. The GRC is supported by the GRC Secretariat, which provides WHO staff with technical advice on guideline development, sets 
benchmarks and evaluates guideline development processes.
*All content was gathered from WHO Handbook for Guideline Development (Second edition).14
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qualitative descriptive approach described by Sande-
lowski.19 20 Here, the identified themes present a compre-
hensive and rich summary of experiences responding to 
the research objectives. However, Sandelowski proposes 
the use of content analysis as the main analytical 
approach in a qualitative descriptive study, a term used 
interchangeably with thematic analysis, but which many 
consider to be two distinct ways of approaching qualita-
tive data analysis.21
The COnsolidated criteria for REporting Qualitative 
research (COREQ) was used to report on the character-
istics of the research team, study design and data analysis 
(online supplementary file S1).22 COREQ was originally 
developed to promote transparent and comprehensive 
reporting of qualitative health research involving the 
use of interviews and/or focus groups to explore pref-
erences and needs of clinicians, healthcare providers, 
policy-makers and patients. However, its relevance goes 
beyond research on interactions within healthcare systems 
since COREQ’s items clarify various choices important 
for understanding the study design, the collection and 
the interpretation of qualitative data more generally.
document review
To gain a deeper understanding of WHO’s guideline 
development process, inform the development of the 
study’s research objectives, and help interpret the main 
findings in a broader context, a comprehensive literature 
review was conducted to identify and summarise research 
articles that have previously examined WHO’s experience 
with its guideline development reforms. PubMed, SSRN 
and Web of Science were searched combining the 
keywords ‘World Health Organization’ and ‘guideline 
development’. Three additional studies not identified 
through this search were also included.6 8 11 A summary 
of all included studies’ methodologies and key findings 
are available in online supplementary file S2. Studies that 
did not evaluate the guideline development process, but 
only described the development of specific guidelines, 
were excluded.23
semistructured interviews
This research project and the proposed research questions 
were discussed with one very senior leader within WHO, 
who made an initial email introduction inviting directors 
of technical departments and coordinators of various tech-
nical programmes to participate in the study. These direc-
tors and coordinators either agreed to participate them-
selves, forwarded the request to other WHO staff respon-
sible for convening scientific advisory committees within 
their respective departments or did not respond. A list of 68 
potential WHO interviewees was generated through purpo-
sive and snowball sampling, and all of these were invited to 
participate in the study. Of these 68 people, 1 was no longer 
at WHO, 3 felt their work was not relevant for the study, 3 
declined due to busy schedules, 6 forwarded the request to 
other staff they deemed more suitable for the study and 14 
did not respond to the invitation. In total, 41 senior WHO 
staff were interviewed between March and June 2016. Six of 
these interviews were conducted by SJH (male, PhD, lawyer) 
at WHO headquarters in Geneva to pilot the scope and rele-
vance of the study, gain clarity on the range of scientific advi-
sory committees at WHO and revise the interview questions 
to maximise their clarity and probative value. These pilot 
interviews did not intend to explore the inner workings of 
WHO’s guideline development processes; accordingly, these 
six interviews were not audio recorded and transcribed, 
and the data was not included in the formal analysis. The 
remaining 35 interviews were conducted by UG (male, PhD, 
physician). Both authors have previous experience working 
with processes informing WHO guidelines and strate-
gies,24–26 and conducting and publishing studies involving 
qualitative methods to explore research questions on the 
role of national and international institutions in global 
health.27 28
Every participant was sent an email prior to the inter-
view introducing the interviewer and the project, which 
included a concept note about the project. Thirteen 
interviews were conducted in-person at WHO’s head-
quarters in Geneva and 22 interviews were conducted by 
telephone. The interview questionnaire (online supple-
mentary file S3) was designed to address key questions 
pertaining to the design and effectiveness of scientific 
advisory committees. The interviews were conducted 
using a semistructured format, permitting some itera-
tions to the questions depending on the response of the 
interviewees, and flexibility to address interesting themes 
emerging from responses. Participants were interviewed 
box 2 Two general recommendations and three specific 
actions for WHo
Two general recommendations
 ► Guideline development processes in technical health agencies and 
institutions should learn from WHO’s vast experience with imple-
menting independent evaluation, monitoring and feedback for pro-
cess and quality to ensure the legitimacy of recommendations.
 ► Guideline development processes at WHO should be designed to 
better acquire, assess, adapt and apply the full range of research 
evidence that can inform recommendations about health systems 
and public health.
Three specific actions for WHo
 ► WHO should foster the systematic sharing of experiences and learn-
ing among its departments that are or are planning to engage with 
guideline development processes so as to promote continuous pro-
fessional development of its staff.
 ► WHO should share its experience externally (such as with the 
GRADE (Grading of Recommendations Assessment, Development 
and Evaluation)  Working Group and its subgroups) as part of an 
effort to further optimise the guideline development processes to 
meet the needs of health systems and public health interventions 
(eg, complex interventions).
 ► WHO should consider whether outputs from scientific advisory 
committees that currently operate outside of the formal guideline 
development rules should be subject to a centralised quality assur-
ance process.
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individually, except for three participants who were 
based in the same WHO department and interviewed 
together. Only the interviewees were present in the room 
during the interviews. No repeat interviews were carried 
out. With informed consent, the 35 interviews were audio 
recorded, transcribed and anonymised. The interviews 
lasted between 45 and 60 min. We categorised inter-
viewees into five main groups: 
1. Directors of technical departments who had experi-
ence overseeing development of WHO guidelines and 
other forms of scientific advice (n=7).
2. Coordinators and team leaders of technical units with-
in departments with responsibilities for managing 
guideline development processes or scientific adviso-
ry committees, including WHO’s expert committees 
(n=19).
3. Technical officers responsible for supporting guide-
line development processes or other types of scientific 
advisory work at WHO (n=4).
4. WHO staff with other roles, such as senior advisory 
roles or organisational management (n=3).
5. Staff with leadership positions in programmes or part-
nerships hosted by WHO and with responsibilities for 
overseeing scientific advisory work (n=2).
Of these 35 interviewees, 16 had in-depth experience 
with WHO’s guideline development processes, while 
the remaining interviewees primarily dealt with other 
types of scientific advisory functions at WHO (such as 
WHO’s expert committees or scientific and technical 
advisory groups). On average, the interviewees had 
13 years of experience working at WHO (range 0.5–32 
years). Interviewees had experience working on various 
technical issues, including antimicrobial resistance, child 
health, environmental health, essential medicines and 
pharmaceutical policy, health workforce, HIV/AIDS, 
humanitarian response, immunisation and vaccine safety, 
maternal and reproductive health, non-communicable 
diseases and nutrition, polio, tobacco control, tubercu-
losis and social determinants of health.
data analysis
The process for identifying major themes in the qualita-
tive data followed the general five-cycle process described 
by Yin,16 which represents an iterative approach involving 
five phases: (1) compiling, (2) disassembling, (3) reassem-
bling, (4) interpreting and (5) concluding. While each step 
addresses specific aspects of data analysis, we moved back 
and forth between phases 2 and 4 as part of continuously 
revisiting the accuracy of initial coding and interpretation 
of the data. Compilation consisted of transcribing and further 
deidentifying each audio recording, including removing 
specific mentions of names, titles and departments, which 
may indirectly identify the interviewee. Disassembling 
consisted of open coding where level 1 codes, including 
in vivo codes, were assigned to words, phrases and larger 
fragments of each interview transcript. During this phase, 
relationships between level 1 codes from different inter-
views were identified and assigned level 2 codes, thereby 
facilitating an incremental understanding of the major 
themes from across the interviews. The reassembling phase 
consisted of bringing level 1 and level 2 codes together 
to identify themes representing a central concept and/or 
message that captured recurring patterns observed across 
the interviews. The codes and patterns deemed most relevant 
for the study questions were continuously refined through 
an iterative process and by using the constant comparison 
method inspired from grounded theory.16 We observed that 
the last five to six interviews only introduced a few new codes 
and no new major themes, which we used as the indication 
for reaching data saturation. During the interpretive phase, 
we used the reassembled data to write a narrative around the 
study questions, while continuously assessing whether revis-
iting the disassembling and reassembling phases was needed 
to recompile the data. Field notes and memos documenting 
observations and reflections during and after the interviews 
(eg, whether interviewees emphasised particular aspects 
or the investigator’s initial comparisons of issues raised in 
the interview with those raised in previous interviews) were 
considered during all stages of the analysis.
The qualitative data was transcribed and coded by one 
investigator. After initial identification of level 1 and level 2 
codes and their associated themes by UG, the findings were 
discussed in detail with the second investigator (SJH) and 
refined until agreement was reached about the fit of the 
codes with the identified central themes and messages. We 
provided interviewees with two opportunities to comment, 
make suggestions or raise any concerns with our data anal-
ysis and interpretation. First, we sent each interviewee the 
full transcript and a 1–2 page summary of their interview. 
These summaries were sent approximately 1 year after the 
interviews were conducted. Second, we sent all interviewees 
an early draft of this manuscript prior to submitting it to 
BMJ Global Health. Overall, 14 of 35 interviewees confirmed 
receiving the summary and/or the manuscript, while the 
remaining interviewees did not respond. One interviewee 
explicitly expressed disagreement with how the findings 
were presented, although did not object to the content. 
To further validate our findings, we sent the manuscript to 
two WHO staff with extensive experience with the agency’s 
guideline development processes—but who were not inter-
viewed for this study—for their feedback. They expressed 
that they recognised the main findings of the study.
Four major themes pertaining to WHO’s guideline devel-
opment process were identified from the analysis of the 
interviews. The qualitative codes related to these themes are 
presented in table 1. During the concluding phase, the inter-
pretation of the main empirical findings formed the basis 
for two main recommendations proposed under discussion.
ethics
An exemption to ethical review was granted for this study 
by the University of Ottawa’s Office for Research Ethics 
because the study was considered a programme evalu-
ation in accordance with Canada’s Tri-Council Policy 
Statement (TCPS2) on the Ethical Conduct for Research 
Involving Humans.29
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resulTs
WHo’s guideline development reforms represented a 
transformational shift in its approach to producing clinical 
and public health recommendations
It was widely recognised among WHO interviewees 
that earlier criticisms of WHO’s old guideline devel-
opment process were appropriate and that reforms 
were needed due to the widespread reliance on 
expert opinion and ad hoc processes rather than 
structured processes informed by synthesised research 
evidence. For example, according to one WHO 
interviewee:
 … it was felt that this is just a bunch of expert opinions that 
is coming together. Who you happen to pick on that com-
mittee was going to define what the outcome was going 
to be. It was felt that WHO was handpicking and forcing 
themselves to a particular outcome that a small group of 
people at WHO wanted. (WHO Interviewee 9)
Table 1 Major themes and corresponding qualitative codes
Themes Level 2 codes Level 1 codes
WHO’s guideline development 
reforms represented a 
transformational shift in its 
approach to producing clinical and 
public health recommendations
Triggers of the reform Dominance of expert opinion
Impact of the reform Handbook with comprehensive guidance
Transformed WHO’s guideline development 
process
Institutionalisation of evidence-based principles
More consistent use of systematic reviews
Independent evaluation and 
feedback by the GRC has 
strengthened the legitimacy 
of the decision-making 
processes underlying WHO’s 
recommendations
Independent evaluation strengthens 
legitimacy
GRC process has helped recommendations stand 
up to criticism
WHO guideline development 
efforts are not yet designed to 
systematically make use of all 
relevant research evidence needed 
to inform decisions about complex 
interventions
Challenges with retrieving and 
appraising evidence to inform 
complex interventions
Nature of WHO guidelines becoming more 
complex
Evidence from beyond RCTs needed to inform 
recommendations
Challenges with formulating systematic review 
questions that capture broader range of evidence
Challenges with and perceptions 
about GRADE
GRADE struggling with qualitative evidence
Dissatisfaction with how GRADE evaluate non-
randomised study designs
Challenging with rigid application of GRADE
GRC process perceived rigid/complicated
Misperceptions about GRADE only being 
applicable to evidence from RCTs
Need for more sophisticated understanding of 
GRADE
Dialogues to address challenges Increasing awareness within GRC about 
difficulties
Constructive dialogue with GRC and 
methodologists crucial
GRADE approach evolving to become more 
applicable to broader range of evidence
WHO’s guideline development 
reforms do not currently apply to 
all outputs published from all of 
WHO’s technical units and scientific 
advisory committees
Bypassing of formal guideline 
development process
Guidance being issued outside process overseen 
by GRC
Tempting to circumvent GRC process
All issued guidance could benefit from 
independent evaluation, monitoring 
and feedback
Disorganised approach to managing guidance 
produced outside GRC requirements
Similar quality assurance needed for other 
guidance 
GRADE, Grading of Recommendations Assessment, Development and Evaluation; GRC, Guidelines Review Commitee; RCT, randomised 
controlled trial.
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The consistent use of systematic reviews was described 
to be “the major change introduced with the guide-
line process”, with the aim being to “stop WHO relying 
only on expert opinion” (WHO Interviewee 16). The 
reformed guideline development process was described 
to represent a transformational shift in how WHO devel-
oped clinical and public health recommendations, with 
one interviewee arguing that “how things are being 
done now is totally different from ten years ago” (WHO 
Interviewee 22). It was felt that the reforms overall had 
improved the quality of WHO’s recommendations:
Yeah, it is a long process that costs time and money because 
you have to commission the systematic reviews which take 
time. But then, at the end, you have a document and no 
one can come and tell you, ‘OK, why this?’ because you 
have the evidence, you can show the evidence supports the 
recommendations. I think that is a good thing for WHO. 
(WHO Interviewee 18)
Independent evaluation and feedback by the GrC has 
strengthened the legitimacy of the decision-making 
processes underlying WHo’s recommendations
Several interviewees observed that guidelines from WHO 
frequently meet opposition, especially when recommen-
dations challenge commercial interests and WHO subse-
quently face “strong push-back from the industry” (WHO 
Interviewee 13). Accordingly, many interviewees high-
lighted the important role of the GRC as a quality assur-
ance mechanism for recommendations from WHO. 
Interviewees described the GRC to be an institutional 
mechanism for independent evaluation and feedback 
to ensure that appropriate procedures were followed. It 
was reported that the GRC had contributed to strength-
ening the legitimacy of decision-making processes under-
lying WHO’s recommendations. For example, two inter-
viewees expressed:
It [the GRC] safeguards the procedural issues to say the 
members of the guideline development group were all 
vetted for conflict of interest, the meeting was done ac-
cording to the procedures of the GRC, so we have that as-
surance. Even when we have serious challenges, letters of 
complaints, for example written to ethics committees, that 
helped us make our case on the process, but also on the 
technical recommendations. (WHO Interviewee 14)
As long as you have something like a GRC mechanism that 
screens everything in the end, where people can go and 
say ‘this is how we did it’, these are the members, this is the 
process, and so it has been done well. (WHO Interviewee 
22)
WHo guideline development efforts are not yet designed to 
systematically make use of all relevant research evidence 
needed to inform decisions about complex interventions
Although WHO interviewees generally expressed support 
for the guideline development reforms, many inter-
viewees argued that the guideline development process 
in its current form is not designed to consider the full 
range of evidence that can inform health systems and 
public health recommendations. Two major challenges 
were highlighted by the interviewees.
First, some interviewees expressed that research ques-
tions for systematic reviews could be formulated very 
narrowly such that they did not capture the broader 
range of evidence needed to make nuanced recommen-
dations about health systems and public health issues. 
One interviewee explained:
I think that in some cases, there most probably is a ten-
dency to pose too many peephole questions in areas where 
you’re not going to have the evidence, so you’re going 
through your systematic review and the outcome is very 
confusing. (WHO Interviewee 20)
Another interviewee described the challenge to be 
that “the definition of a systematic review is being set so 
narrowly that it’s hard to bring in other kinds of relevant 
information to the table” (WHO Interviewee 9). Accord-
ingly, interviewees emphasised the need for guidelines 
about health systems and public health interventions to 
consider evidence generated by non-randomised study 
designs and systematically documented programme 
experience, especially in order to produce guidance 
about how to implement and scale-up interventions. For 
example, two WHO interviewees explained:
… because some of the richness of how you scale it up and 
make it work in the field is quite distinct from RCTs [ran-
domised controlled trials], or when you review RCTs, you 
basically exclude a vast amount of knowledge which is pow-
erful knowledge in the field. (WHO Interviewee 15)
It is becoming challenging because on clinical interven-
tions or something very medical, RCTs are fine and they 
produce the right sort of evidence. Increasingly, we are 
producing evidence around programmatic issues, service 
delivery programs, health systems functioning, social inter-
ventions, behavioural change, etc, and when you are look-
ing at providing evidence on how programs should func-
tion, RCTs are generally not the best source of evidence.
(WHO Interviewee 28)
Second, several interviewees expressed dissatisfaction 
over the current use of the GRADE approach for evalu-
ating the quality of the evidence informing guideline devel-
opment, raising two main concerns. The first was about 
GRADE being designed to assess the evidence for the effec-
tiveness of interventions, but struggling “with how to inter-
pret qualitative research findings” (WHO Interviewee 14). 
The second was about how the GRADE process rated the 
quality of evidence generated from non-randomised study 
designs and that most often the quality of evidence from 
these studies was rated as ‘low’. It was argued that in these 
cases, consistent results from multiple well-designed obser-
vational studies should lead to a more favourable rating of 
the quality of the evidence, especially when interventions 
and policies cannot be tested with randomised controlled 
trials (RCTs) due to ethical, legal or logistical reasons. For 
example, two interviewees expressed:
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I still have a problem with, you know, if you have ten stud-
ies by ten different investigators, finding the same results, 
[and] not giving that benefit versus if you have only one 
study. Think about it the way you want, but for me there is 
more evidence with ten different studies from ten different 
investigators with ten different methodologies, so we try to 
advocate for increasing quality because of the consisten-
cy. But currently consistency is used only to downgrade. 
(WHO Interviewee 12)
It does mean that when you score the grade using the 
GRADE tool, because it’s not a randomized control trial, it 
tends to say that the ‘oh, the level of evidence is low’, when 
this is going to be always the highest-level of evidence that 
you can have and it’s been replicated and done in many 
other places. (WHO Interviewee 31)
In relation to these concerns, interviewees expressed 
“there is too much rigidity in the way it’s currently handled” 
(WHO Interviewee 12) and that some methodologists had 
“pushed a very rigid approach on the organization” (WHO 
Interviewee 16). Similarly, another interviewee argued that 
more flexibility and a better balance have to be found in 
order to adequately make use of all available evidence:
I think the WHO swung the pendulum too far to the oppo-
site of the extreme, trying to make things so pure and so 
unbiased that it left out the depth of understanding of the 
issues, and left out the depth of understanding the litera-
ture around an issue … We don’t want it to be like it was 
before, but I think we pushed it too far, we need to come to 
something that is a little bit more balanced between those 
two approaches. (WHO Interviewee 9)
However, others argued that the “GRADE process does 
allow for consideration of all types of evidence,” and that 
“it’s most probably the interpretation of the GRADE 
process that most probably distracts from a reasonable 
decision-making process” (WHO Interviewee 20). It was 
argued that the guideline development process and the 
GRC suffered from an internal perception problem in 
that “people think GRADE means RCTs” and that “it’s a lot 
about people being a lot more sophisticated in their under-
standing of it” (WHO Interviewee 16). In line with this, 
other interviewees expressed that a constructive dialogue 
with the GRC and methodologists, and guidance about the 
GRADE approach had proved helpful in improving their 
understanding about the guideline development process 
and adapting it to their specific context and needs:
Then the new methods expert that we had was much more 
flexible and was willing to work with us to see how GRADE 
can be applied to the kind of the studies which are mainly 
providing the evidence from our area of work. (WHO In-
terviewee 7)
I think that it can look very difficult and challenging, but 
when you discuss with the committee [GRC], they can give 
you ways to address it and adapt it to your problem. (WHO 
Interviewee 18)
Several interviewees described that conversations 
were occurring both within various departments—and 
between those managing guideline development efforts 
and the GRC—about this challenge, but that it remained 
to be seen how the agency and the GRC will ultimately 
deal with it:
I think the GRC has become more open to those kinds 
of dialogues, but it’s kind of outside the normal process, 
so you have to set it up as ‘here’s an exception, and why 
do we have to justify this exception’. And I think we are 
moving in the right direction, but it is already a prob-
lem that the whole structure is kind of set up, it has to 
be handled as a special case as opposed to setting it up 
to bring a broad body of evidence to the table. (WHO  
Interviewee 9)
WHo’s guideline development reforms do not currently apply 
to all normative outputs published from all of WHo’s technical 
departments and scientific advisory committees
Many interviewees reported being involved with WHO 
advisory bodies known as ‘scientific and technical advisory 
groups’. These bodies were described as “more informal 
than a guidelines review group because it’s not tasked with 
making necessarily policy recommendations on treatments 
and use of diagnostics” (WHO Interviewee 15). Another 
interviewee characterised these bodies as not primarily 
dealing with scientific questions and technical issues, but 
rather the strategic direction of various WHO programmes:
It’s an advisory body, and it’s not just science and technical 
issues but it’s also strategic issues for our programmatic re-
sponse, so in that way it operates slightly differently from 
a group that would convene around one piece of scientific 
policy. But it broadly reflects on guidelines produced and 
the overall strategic direction for our program and fulfill-
ing WHO’s core functions. (WHO Interviewee 17)
However, several interviewees described these bodies as 
also producing guidelines and policy recommendations 
that should be subjected to the formal guideline develop-
ment process. For example, one interviewee expressed 
that “from time to time, we most probably are putting 
out guidance that should really be graded for guideline 
recommendations” (WHO Interviewee 19). Interviewees 
also described cases of strategic attempts by WHO staff to 
circumvent the mandated guideline development process 
that is quality assured by the GRC. One interviewee raised 
that the resources and rules associated with the guideline 
development process could tempt staff to frame guidance 
documents in ways that enabled them to bypass the formal 
route, which risked issuing WHO recommendations without 
bringing all the available scientific evidence to the table:
So you’re trying to figure out how do I frame this so that it 
doesn’t really sound like a WHO guideline, so that I don’t 
have to deal with all that process … Except that if you 
don’t have to go through the rigorous process, then you’re 
kind of on your own, you can do whatever you want to do. 
There’s no oversight, there’s no guidance on what ought to 
be part of that, and I think you end up not making the best 
recommendations. (WHO Interviewee 9)
Another interviewee expressed concerns about the agency 
having a “completely disorganized approach to managing 
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anything outside of the GRC or the expert committee 
processes” and that there exist “examples of groups that 
are informal that do not follow any procedures” (WHO 
Interviewee 16). Further concerns were raised on whether 
these scientific advisory committees produced advice that 
was in keeping with WHO’s policies and standards (WHO 
Interviewee 1). It was suggested that there is scope for these 
outputs to be captured by a more centralised quality assur-
ance process that cover all WHO outputs:
If GRC was being set up again, you would try to say every-
thing goes through the committee, you would probably 
have a slightly different looking committee, and a slightly 
different handbook, but the bypass route should not be al-
lowed. (WHO Interviewee 16)
dIsCussIon
This study aimed to understand how WHO has responded 
to the reforms made to its guideline development process 
over 10 years ago, including the major changes it made in 
2007, the progress and impact of these changes to date, 
and key challenges that need to be addressed. Informed 
by the semistructured interviews with WHO staff and 
previous studies on WHO’s guideline development 
process, we propose and discuss two recommendations 
that can inform efforts to improve the guideline develop-
ment efforts of technical health agencies like WHO and 
others at the local, national and international levels.
recommendation 1: Guideline development processes in 
technical health agencies and institutions should learn from 
WHo’s vast experience with implementing independent 
evaluation, monitoring and feedback for process and quality 
to ensure the legitimacy of recommendations
One major factor contributing to the legitimacy of a 
health recommendation is the underlying evidence base, 
or in other words, the extent to which recommenda-
tions are consistent with the quality of available research 
evidence. Our study did not quantitatively address this 
question, but other studies suggest that there is still room 
for WHO to improve. For example, one study found that 
over 50% of strong WHO recommendations are based on 
assessments of evidence that place low or very low confi-
dence in effect estimates (known as ‘discordant recom-
mendations’), with the majority of these being incon-
sistent with the GRADE approach.6 12
However, the strength of the evidence alone is insuf-
ficient to ensure the legitimacy of a recommendation. 
A second major contributing factor to legitimacy is the 
decision-making process through which the recommen-
dations are developed.30 Good process is particularly 
important in cases where recommendations might impli-
cate commercial or ideological interests. A strategy that 
interested actors often use to challenge the legitimacy of 
recommendations, even in cases where the underlying 
evidence base is strong, is to question the process by 
which guidelines were generated, including the selection 
of experts or the participation of relevant stakeholders.
One way of strengthening the legitimacy of deci-
sion-making processes and protecting recommenda-
tions from undue criticism is to ensure that the process 
followed was subject to independent evaluation, moni-
toring and feedback for quality. WHO has over 10 years 
of accumulated experience with implementing its GRC 
mechanism, which can be seen as an internal quality 
assurance mechanism augmented by external expertise. 
Its assessments are made independently of WHO’s senior 
management and its Member States. Accordingly, the 
GRC can be seen to serve two roles: (1) represent an insti-
tutional mechanism for independent evaluation that can 
strengthen the legitimacy of the decision-making process 
underlying the recommendations and (2) by involving 
staff internal to the agency support gradual institution-
alisation of evidence-informed principles and processes. 
Learning from WHO’s experience with implementing 
independent evaluation, monitoring and feedback for 
process and quality to ensure the legitimacy of recom-
mendations can be relevant for other technical agencies 
and institutions responsible for guideline development 
on health issues.
recommendation 2: Guideline development processes at 
WHo should be designed to better acquire, assess, adapt and 
apply the full range of research evidence that can inform 
recommendations about health systems and public health
The second recommendation calls for adapting WHO’s 
guideline development process to better enable assess-
ment of the evidence base needed to inform health 
systems and public health interventions, many of which, 
if not all, are ‘complex interventions’.31 Unlike individu-
al-level interventions which can more easily be evaluated 
by randomising study participants to receive either treat-
ment or control, many health systems and public health 
interventions cannot be randomised for ethical, legal 
or logistical reasons, even if governing decision-makers 
are supportive of doing so. Accordingly, evidence from 
non-randomised study designs—for example a well-de-
signed observational study, quasi-experimental impact 
evaluation or systematically documented evidence from 
programme experience—may represent the highest 
quality of evidence one can expect for a public health 
or health systems intervention.9 32 This challenge is not 
unique to guideline development processes at WHO 
but has been debated at various points over the past 
years.14 33–40 It represents an important factor explaining 
why WHO interviewees raised concerns over the guide-
line development process not being flexible enough to 
incorporate and appropriately evaluate evidence from 
non-randomised study designs and qualitative studies. 
Similar views have previously been reported to be held 
by WHO staff9 and guideline panel members,11 41 and 
confirmed by methodologists with experience serving on 
guideline panels.15
Two design features of WHO’s guideline develop-
ment process seem to particularly need adaptation to 
fully incorporate the evidence base needed to inform 
 on 20 S
eptem









ealth: first published as 10.1136/bm






10 Gopinathan U, Hoffman SJ. BMJ Glob Health 2018;3:e000716. doi:10.1136/bmjgh-2018-000716
BMJ Global Health
recommendations. The first design feature is the use of 
systematic reviews to critically appraise relevant research 
underpinning WHO recommendations. Systematic 
reviews are among the cornerstones of guideline devel-
opment processes and are critical for reducing the 
risk of bias and reaching reliable evidence-informed 
conclusions. By way of background, systematic reviews 
are commonly conducted by formulating a clear and 
specific question most commonly using the PICO format 
(population, intervention, comparison, outcome) and 
by having explicit inclusion/exclusion criteria. This 
rigorous approach helps to identify and include studies 
that are comparable and able to respond to questions 
about effectiveness of interventions (what works).36 This 
approach works sufficiently well for evaluating the effec-
tiveness of a medical treatment. However, many health 
systems and public health interventions are ‘complex’ 
interventions, characterised by multiple interacting 
components, requiring the involvement of different 
organisational levels, having a number of different points 
of interactions between interventions and the settings in 
which the interventions are implemented and affecting 
different outcomes.31 37 38 For complex interventions, 
framing systematic review questions too narrowly and 
relying solely on assessing evidence of effectiveness risks 
excluding the broader range of relevant evidence needed 
to inform recommendations. This includes evidence for 
factors important for implementing an intervention, 
for bringing an intervention to scale, for assessing the 
resources needed to implement interventions across 
different settings, for understanding the feasibility and 
acceptability of an intervention, for identifying the 
interactions among various components of complex 
interventions and for probing the systems in which the 
interventions were implemented.42 These represent 
factors that are not easily identifiable if systematic review 
questions are narrow and solely include experimental 
intervention studies focused on safety and effectiveness. 
Currently, the WHO Handbook for Guideline Development 
do not offer comprehensive guidance for adapting the 
PICO format or considering alternative frameworks 
when dealing with systematic reviews for health systems 
and public health interventions.14 In light of new tools 
and frameworks for conducting systematic reviews for 
complex interventions,43 WHO might consider adapting 
its guidance.
The second design feature of WHO’s guideline devel-
opment process that has led to it being viewed as inflex-
ible involves the approaches and tools used to evaluate 
the quality of the evidence base. At WHO, the GRADE 
approach has been the main tool for assessing the 
quality of the evidence underlying recommendations. 
This study’s findings highlight three aspects associated 
with GRADE that seem to have reinforced the view 
among many WHO staff that guideline development 
processes are not designed to incorporate a broader 
evidence base. The first is an insufficient understanding 
among many people involved in guideline development 
processes about the purpose, utility and implementa-
tion of the GRADE approach. This was also highlighted 
by Sinclair et al in their evaluation of WHO’s guideline 
development process,9 suggesting that better under-
standing of GRADE among WHO staff involved with 
guideline development needs continued attention. To 
this end, guidance to promote a more sophisticated 
understanding of GRADE has been issued (including 
by the GRADE Working Group),40 but greater aware-
ness and wider implementation is needed at WHO. The 
second aspect is GRADE’s initial rating of certainty in the 
evidence from non-randomised study designs as ‘low’. 
This is a feature of GRADE that guideline developers 
beyond WHO have raised concerns over, since in fields 
where RCTs are sparse or not feasible, the quality of the 
evidence rarely will be rated as ‘high’ or ‘moderate’13; 
fortunately, this is a criticism that the GRADE Working 
Group have noted and are seeking to address.44 The 
third aspect is that GRADE was not designed to evaluate 
the quality of evidence from qualitative studies, which 
is increasingly recognised as crucial for informing deci-
sion-makers about the needs, values, perceptions and 
experiences of stakeholders important for an interven-
tion, and the system-level factors affecting implemen-
tation.41 45 The reliance, at least until very recently, 
on GRADE as the sole tool for assessing the body of 
evidence might have created a perception that guide-
line development processes are not intended to incor-
porate a broader evidence base, including qualitative 
evidence. These concerns over GRADE raised by WHO 
staff in our study align with challenges highlighted by 
others.14 32 46 47
On all of these fronts, there have been recent devel-
opments worth noting. For evaluating non-randomised 
study designs, the ROBINS-I tool (Risk Of Bias In 
Non-randomized Studies-of Interventions) has been 
developed, with further extensions planned.48 Using 
ROBINS-I as part of GRADE assessments can enable 
better comparisons of evidence from non-randomised 
study designs and RCTs, as well as more detailed 
assessments of different types of non-randomised 
study designs (such as rating evidence from a well-de-
signed interrupted time series studies higher than 
conventional non-randomised study designs), thereby 
addressing one of the major concerns raised by WHO 
interviewees.
For evaluating the quality of qualitative evidence, 
WHO has together with collaborators taken a leader-
ship role. Its own guideline development process for 
recommendations about optimising health worker 
roles for maternal and newborn health expanded the 
evidence base beyond safety and effectiveness,41 leading 
to the development of a new approach for assessing the 
confidence that can be placed in qualitative evidence—
the Grading of Recommendations, Assessment, Devel-
opment and Evaluation—Confidence in Evidence 
from Reviews of Qualitative Research (GRADE-CER-
Qual) tool.49 GRADE-CERQual has later been further 
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developed and implemented as part of WHO guide-
line development processes,45 addressing yet another 
concern raised by WHO interviewees. Moreover, the 
Evidence-to-Decision Framework developed by the 
DECIDE project creates space for the assessment of 
an intervention’s acceptability and feasibility and is 
increasingly being used in WHO’s guideline develop-
ment processes.50–52 Finally, the challenges with synthe-
sising and assessing the quality of evidence for complex 
interventions, and the need for guidance and tools 
are increasingly recognised, both within and beyond 
WHO.43 53
specific actions for WHo
We identify at least three specific areas where action 
could be taken by WHO (box 2). First, there should be 
more frequent and systematic sharing of experiences 
among WHO departments and between the GRC and 
the various departments that develop guidelines. Such 
sharing and continuous professional development for 
WHO staff would help address the many issues raised by 
this study and others.9 11 15 Second, the guideline devel-
opment process should be further enhanced to meet 
the needs of health systems and public health interven-
tions, which is consistent with recent calls in peer-re-
viewed journals from senior WHO staff.54 It is therefore 
timely that efforts are underway to examine extensions 
to the GRADE approach,55 as well as efforts led by the 
GRADE Working Group to integrate GRADE assess-
ment with the use of tools such as ROBINS-1.44 More-
over, WHO has internally recognised this and other 
challenges with its guideline development process56 
and initiated its own process for improving retrieval, 
synthesis and assessment of evidence on complex 
health interventions, which might inform future 
changes to the design of WHO’s guideline development 
process.53
Finally, WHO should consider whether all products 
containing advice and guidance that emerge from the 
plethora of WHO’s technical departments and scien-
tific advisory committees—many of which currently 
operate outside of the GRC’s mandate—could benefit 
from a centralised quality assurance process inde-
pendent of WHO Member States, similar to what is 
currently performed by the GRC for WHO’s formal 
guidelines. This may improve quality and legitimacy, 
but it will also require resources, time and planning. 
On this front, a recent development is that WHO has 
proposed in its draft 13th General Programme of Work 
to ‘establish guiding principles and quality assurance 
procedures for the design, formulation and dissemina-
tion/follow-up of all normative products (all normative 
products, including strategies, road maps and global 
action plans will be based on agreed standards and 
reviewed independently, as is the case for technical 
guidelines), including maximizing the use and engage-
ment of top international experts’ 57—a proposal 
informed by a 2017 review of WHO’s normative 
functions.58
strengths, limitations and reflections on study design and 
data analysis
We identify three main strengths and two main limi-
tations of this study. The first strength is the large 
number of interviewees (n=16) who had experience 
with WHO’s guideline development process, as well 
as additional interviewees (n=19) working with other 
structures that produce scientific advice (eg, expert 
committees, scientific and technical advisory groups), 
which enabled us to consider WHO’s broader context 
when interpreting our findings. A second strength is 
that the majority of the interviewees were senior WHO 
staff who have been working for the agency since before 
the guideline development reforms were initiated and 
therefore were able to inform our study with their 
experiences before and after the reforms. The third 
strength is the diversity in technical areas represented 
by the interviewees, which enabled us to identify themes 
that were relevant to guideline development processes 
across WHO’s technical areas. The invited WHO staff 
who for various reasons decided to not participate in 
this study did not, with respect to roles and technical 
areas, differ from those who were interviewed since we 
managed to recruit interviewees from various levels and 
across the many technical areas of the agency. Overall, 
our analysis was informed by a large amount of quali-
tative data consisting of diverse sets of relevant experi-
ences accumulated over a long period of time.
The first main limitation is that the study was initially 
conceived to examine the design features of WHO’s 
scientific advisory committees in general, and not 
specifically to evaluate WHO’s guideline development 
reforms. We may therefore have overlooked asking 
important questions that could have deepened insights 
about WHO’s experience with its reformed guideline 
development process. For example, while all inter-
viewees emphasised the importance of diverse repre-
sentation in guideline development groups, we did 
not probe in detail their experience with involving 
populations affected by the recommendations during 
guideline development—which is another important 
factor affecting the legitimacy of recommendations. 
The second main limitation is social desirability bias—
that WHO interviewees may have responded in a way 
that casts the agency in a favourable light, downplaying 
internal weaknesses and challenges. However, the 
majority of interviewees provided candid assessments 
of the agency’s progress and challenges with guideline 
development and producing scientific advice. More-
over, some also spoke rather critically of the agency, such 
that we do not believe the results are unduly biased 
in this way.
Finally, choices made during data analysis are worth 
discussing in light of different views and traditions with 
respect to improving reliability in qualitative research. 
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In our study, both investigators discussed and reached 
agreement about the identified themes and the fit of 
the coding with these themes. However, we did not 
implement independent coding by two investigators; 
rather, one investigator undertook the initial coding 
and identification of preliminary themes, which were 
subsequently discussed and refined in dialogue with 
the second investigator. This strategy may be seen as 
a weakness by researchers who argue that multiple, 
independent coding and calculation of inter-rater reli-
ability is a prerequisite for rigour and trustworthiness 
in qualitative research.59–61 However, our approach is in 
line with strategies undertaken and advocated by many 
qualitative researchers, including Braun & Clarke who 
have developed an approach to thematic analysis which 
closely resemble the analytical strategy undertaken in 
this study.18 62 They and others argue that there is no 
‘one’ accurate way of coding and interpreting qualita-
tive data and that it is unrealistic to expect different 
researchers to reach exactly the same insights from 
qualitative data, since they may differ in disciplinary 
backgrounds and theoretical starting points. What 
remains important is full transparency about choices 
made during data analysis so that others can evaluate 
how these choices may have affected analysis and inter-
pretation. Moreover, it remains important to otherwise 
minimise the risk of misrepresenting the qualitative 
data. To address the former, we have described our 
approach to data collection and analysis in great detail 
in the Methods section. To address the latter, we imple-
mented participant checking. While less than half of 
the interviewees responded to our queries, only one 
interviewee raised objections with the way the findings 
were presented. We assume, but cannot be completely 
certain, that if other interviewees had similar objec-
tions, they would have expressed these after receiving 
the interview summaries or the manuscript. Moreover, 
two WHO officials who were not interviewed for this 
study, but with extensive in-depth experience with 
WHO’s guideline development process, reviewed the 
manuscript and reported to recognise the experiences 
and key challenges identified by our study. Overall, we 
believe that the reported findings and interpretation 
do not misrepresent the interview data, but accept that 
these findings could be interpreted differently by other 
researchers. We therefore invite continued debate on 
issues raised by this study.
ConClusIon
Since WHO initiated reforms to its guideline develop-
ment process, the agency has advanced towards a more 
transparent and rigorous evidence-informed process 
for crafting its recommendations. The ‘culture change’ 
senior WHO staff called for over 10 years ago appears 
gradually to have spread throughout the agency.2 
However, at least two major challenges remain for 
WHO: (1) ensuring that all issued guidance benefits 
from independent evaluation, monitoring and feedback 
for process and quality and (2) adapting its guideline 
development processes to better acquire, assess, adapt 
and apply the full range of evidence that can inform 
recommendations.
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